Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Start-Up Tries Crowdfunding To Revive Brain Cancer Drug Berubicin

Executive Summary

Emerging Company Profile: Texas start-up CNS Pharmaceuticals sees a bright future for blood-brain barrier-crossing berubicin, which is nearing the end of its patent life.

You may also be interested in...



Immuno-Oncology Outlook: Looking For Brain Cancer Options

Scrip analyses the potential of "hot" immunotherapy mechanisms, such as PD-1 inhibitors and CAR-T therapies, in various stages of clinical development for glioblastoma.

Avastin QoL Data In First-Line Glioblastoma Muddy Expansion Plans

Genentech’s bevacizumab was associated with improved maintenance of baseline quality of life and performance status in a confirmatory trial conducted under accelerated approval, but an NCI-funded study found higher rates of neurocognitive decline, increased symptom severity and decline in health-related quality of life.

R&D Realities Disturb Dreams About Orphan Brain Cancer Blockbusters

Developing drugs for the rare, aggressive glioblastoma, the most common and malignant type of glioma, or brain cancer, was never easy. But a brain cancer drug’s journey through Phase III and to the finish line of market entry today is more arduous than ever.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1131690

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel